Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum-Reference-Cited by-同舟云学术

Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum

Published:2018-02-23 Issue:5 Volume:67 Page:785-790
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Lamorde Mohammed¹,Wang Xinzhu²,Neary Megan³,Bisdomini Elisa⁴,Nakalema Shadia¹,Byakika-Kibwika Pauline¹,Mukonzo Jackson K⁵,Khan Waheed⁴,Owen Andrew³,McClure Myra²,Boffito Marta²⁴

Affiliation:

1. Infectious Diseases Institute, College of Health Science, Makerere University, Kampala, Uganda

2. Jeffriess Research Trust Laboratories, Department of Medicine, Imperial College, St Mary’s Campus, London

3. Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool

4. St Stephen’s Clinical Research, Chelsea and Westminster Hospital, London, United Kingdom

5. Department of Pharmacology & Therapeutics, College of Health Science, Makerere University, Kampala, Uganda

Funder

St Stephen’s AIDS Trust

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/67/5/785/25496758/ciy161.pdf

Reference18 articles.

1. Antiretroviral dose optimization: the future of efavirenz 400 mg dosing;Boffito;Curr Opin HIV AIDS,2017

2. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study;Carey;Lancet Infect Dis,2015

3. Comprehensive pharmacokinetic, pharmacodynamic and pharmacogenetic evaluation of once-daily efavirenz 400 and 600 mg in treatment-naïve HIV-infected patients at 96 weeks: results of the ENCORE1 study;Dickinson;Clin Pharmacokinet,2016

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model-informed drug development in pediatric, pregnancy and geriatric drug development: States of the art and future;Advanced Drug Delivery Reviews;2024-08

2. Development of a method for the quantitative determination of ritonavir and lopinavir in blood plasma;Ural Medical Journal;2023-12-22

3. Total and Free Blood and Plasma Concentration Changes in Pregnancy for Medicines Highly Bound to Plasma Proteins: Application of Physiologically Based Pharmacokinetic Modelling to Understand the Impact on Efficacy;Pharmaceutics;2023-10-13

4. Mechanistic Modeling of the Drug‐Drug Interaction Between Efavirenz and Dolutegravir: Is This Interaction Clinically Relevant When Switching From Efavirenz to Dolutegravir During Pregnancy?;The Journal of Clinical Pharmacology;2023-06

5. Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model;Drug Metabolism and Disposition;2022-02-11